

## UK National Screening Committee

Is there evidence to alter the current UKNSC recommendation to offer a national screening programme for sickle cell disease to newborn babies? A pilot of the triage approach.

### Topic: Newborn screening for sickle cell disease (SCD)

Delivery date: March 2015

#### Contents

1. Background to the triage reports.....	2
2. Executive summary.....	3
3. Introduction to the condition .....	3
4. Description of the evidence.....	3
5. Methodology.....	6
6. Search strategy .....	6
7. References.....	9

This analysis has been produced by Bazian Ltd for the UK National Screening Committee. Bazian Ltd has taken care in the preparation of this report, but makes no warranty as to its accuracy and will not be liable to any person relying on or using it for any purpose.

## 1. Background to the triage reports

This report is a rapid (triage) assessment of evidence relating to whether the existing national screening programme (NSP) for sickle cell disease (SCD) in newborns should be continued.

For conditions for which population screening programmes are recommended by the National Screening Committee (NSC) the triage process focuses on whether there is new evidence suggesting that the NSP should be stopped.

It consists of an externally produced report on a literature search undertaken to identify whether any papers have been published:

- addressing screening programme cessation
- reporting harms from screening
- reporting balance of harms and benefits from screening

The aim of these reports is to identify any “red flags” that suggest that an NSP needs to be reviewed in greater detail. They do not aim to identify all new literature relating to screening for the condition; instead they focus specifically on evidence relating to the three areas specified above.

If no papers are identified on the above topics, a recommendation to continue the programme is made. If papers on programme cessation or harms from screening are identified, the UK NSC will consider whether further work is necessary before making a recommendation on the topic.

Stakeholders will be contacted for comments on the recommendation and a three month consultation will be hosted on the UK NSC website.

Based on the triage report and stakeholder comments the Committee decides whether to recommend that the issue is considered in more depth. Where further evaluation is considered appropriate, the options may include an evidence summary, primary research, systematic review, cost effectiveness assessment, modelling.

## 2. Executive summary

This triage assessment identified one study with potential relevance to the three questions above, and that related to the possible harms of SCD screening.

This study reviewed published literature on the harms of six newborn screening programmes in the US, one of which was for SCD (Brosco et al. 2006). This was the only directly relevant study identified. The report concluded that their comprehensive search did not find a widespread problem of harm to children with false positive results receiving medical treatment across the six programmes. There were no specific details of the SCD newborn screening programme in the study abstract.

Recommendation: The single relevant study identified suggested that the SCD screening programme in the US has not led to widespread harm. It does not provide sufficient evidence to suggest that the evidence supporting the national SCD screening programme needs to be reviewed in more depth or stopped.

## 3. Introduction to the condition

The current NSP being assessed is newborn bloodspot screening for sickle cell disease (SCD).

Sickle cell disease is the name for a group of inherited genetic conditions affecting haemoglobin. Haemoglobin carries oxygen to the organs of the body and is contained in red blood cells. In sickle cell disorders some red blood cells assume a sickle shape following the release of oxygen. This abnormal shape causes the cells to clump together making their passage through smaller blood vessels difficult. This may lead to blockage of these blood vessels, preventing tissue oxygenation and causing severe pain and organ damage.

They are autosomal recessive conditions so inheritance of an affected gene from both parents results in a disorder whilst inheritance of one abnormal gene results in a healthy carrier.

SCD is one of the conditions currently screened for as part of the NHS newborn bloodspot (NBS) screening programme. This is offered for all newborn babies, with the blood sample usually taken 5 days after birth (in exceptional cases it can be taken between Day 5 and Day 8). The screening test examines for the presence of haemoglobin S.

This external review has searched the literature published between 2006 up to March 2016, and reviewed the results at title and abstract level to establish whether there is evidence:

- indicating that other countries have terminated SCD screening
- reporting harms from SCD screening
- reporting balance of harms and benefits from SCD screening

## 4. Description of the evidence

Forty-nine publications were selected at the first pass sift as being potentially relevant to these three questions based on title and abstract. These were reviewed more closely at abstract level at a second pass appraisal.

No studies were identified which reported cessation of newborn SCD screening programmes, or explicitly weighed up the balance of harms and benefits from SCD screening. One of these 49 publications met inclusion criteria as having relevance to potential harms of screening. Details of this study are extracted in Table 1.

This study was a historical overview which reviewed the published literature on the issue of possible harm from false positive screening results and subsequent inappropriate medical treatment across six US newborn screening programmes including one for SCD. There were no details of the individual screening programmes or specific adverse outcomes in the abstract.

The excluded studies predominantly included surveys of screening programmes, therapy, discussion of reproductive choices for subsequent pregnancies including prenatal screening, and the detection of sickle cell trait and parent understanding/experiences of this. One before-after study from Brazil (Lima 2015) compared the rates of SCD hospitalisation and mortality before and after the introduction of newborn screening. Rates of hospitalisation were significantly higher after introduction of screening, and the age of admission significantly lower. Increases in mortality and age at death were not significant. The study overall concluded that there was underdiagnosis of SCD prior to screening, and the study was excluded as it does not give evidence to suggest harms of screening.

Table 1: Details of relevant studies identified

Publication details	Study details	Population	Intervention/ test and comparator	Main findings	Comments
<b>Screening programme cessation</b>					
No studies identified					
<b>Harms from screening</b>					
Brosco et al. 2006	Historical overview of universal newborn screening programmes in the US. Including a review of published literature on whether universal screening has led to substantial morbidity and mortality from misguided medical treatment of false positives. A “comprehensive search” was reported to be carried out, but other methods not reported	Newborns screened for SCD or 5 other conditions	Universal newborn screening for SCD (which was contrasted with ‘screening’ in at risk populations). Details of the screening and diagnostic tests, or treatments used were not provided in the abstract.	The search “did not reveal a widespread problem of harm ensuing from medical treatment of children with false positive screening test results” No further details were provided.	It was unclear from the abstract whether the study would qualify as a systematic review. No details of the identified literature were described in the abstract, or e.g. proportion of false positives or harms resulting from their treatment
<b>Balance of harms and benefits from screening</b>					
No studies identified					

## 5. Methodology

It is intended that the triage process for each NSP will be performed every three years. This review is the first triage review for SCD and includes literature published in the last 10 years.

Sifting was carried out in two stages. The first pass sift was conducted by an information specialist at title and abstract level, to remove clearly non-relevant material e.g. animal studies, or studies of different screening programmes. The second pass sift was performed by a health research analyst and this sift examined the results more closely at title and abstract level to remove those studies clearly not relevant, and select those meeting inclusion criteria for summary.

The reports focus on high quality studies, i.e. systematic reviews, randomised controlled trials, non-randomised controlled trials, cohort studies or screening programme evaluations that appear at abstract level to have covered potential harms of the NSP, the balance of harms and benefits, or screening programme cessation. Lower level evidence such as case series and case reports, non-systematic reviews, editorials or opinion pieces are not included unless they clearly highlight potential harms of the NSP indicating the need for further evaluation.

Studies on any issues other than the three questions of interest are not included. For example, studies examining cost effectiveness (unless relevant to the UK and highlighting the balance of benefits and harms), or studies assessing modifications to an existing screening programme (e.g. changing age at screening, screening test used, screening interval etc.) would be excluded. Studies evaluating management of the condition are also excluded unless they indicate that the existing treatment is ineffective or harmful, which may suggest that harms of screening outweigh any benefits.

These triage reports are rapid assessments to identify any “red flags” which indicate the need for further assessment of the NSP. They are complemented by consultation with stakeholders to identify any additional issues which may not be represented in the literature identified.

## 6. Search strategy

We searched the following bibliographic databases:

- Medline (via Embase.com)
- Embase
- The Cochrane Library: including the Cochrane Database of Systematic reviews; Cochrane Central Register of Controlled Trials (CENTRAL); Database of Abstracts of Reviews of Effects (DARE); Health Technology Assessment Database (HTA); NHS Economic Evaluation Database (EED)

The searches were limited by date to include studies published since 2006. No language limits were used. Methodological filters were not used as they would not have been appropriate given the focus of the research questions.

The search strategy was developed through testing to identify the best balance between sensitivity and specificity that was fit for purpose. The search strategy used both indexing terms and text words as relevant records could have been indexed in different ways (or not indexed at all). The Embase search strategy was translated for the other databases and adapted to take into account the databases size, coverage and available indexing terms.

The search strategy was based on the PICO framework and combined three major concepts: the population (condition), neonatal screening, and harms from screening or screening programme cessation.

## Embase.com search strategy

```
#1 'newborn screening'/de 13,746
#2 ((neonat* OR newborn*) NEAR/2 screen*):ab,ti 12,206
#3 'mass screening'/de 49,630
#4 'newborn'/de 498,406
#5 #3 AND #4 2,463
#6 #1 OR #2 OR #5 19,026
#7 ceas*:ab,ti OR cessation:ab,ti OR stop:ab,ti OR stopped:ab,ti OR continu*:ab,ti OR
discontinu*:ab,ti 1,265,546
#8 appropriate*:ab,ti OR inappropriate*:ab,ti OR unnecessary:ab,ti OR question*:ab,ti
1,495,204
#9 harmful:ab,ti OR harm*:ab,ti OR adverse:ab,ti 609,591
#10 benefit*:ab,ti AND (risk*:ab,ti OR harm*:ab,ti) 166,742
#11 'side effect'/exp 398,996
#12 (side NEAR/1 effect*):ab,ti 268,067
#13 overdiagnosis:ab,ti OR 'over diagnosis':ab,ti 3,449
#14 'patient safety'/exp 68,643
#15 'risk assessment'/de 369,811
#16 'risk benefit analysis'/exp 43,498
#17 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 3,964,755
#18 #6 AND #17 4,073
#19 'sickle cell anemia'/exp 29,733
#20 'hemoglobin s'/de 4,111
#21 'hemoglobin sc disease'/de 544
#22 'sickle cell':ab,ti OR scd:ab,ti OR sc:ab,ti AND disease*:ab,ti 29,324
#23 'sickle anaemia':ab,ti OR 'sickle anemia':ab,ti 21
#24 'hbs disease':ab,ti OR 'hb ss disease':ab,ti 45
#25 'hemoglobin s':ab,ti OR 'haemoglobin s':ab,ti 1,788
#26 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 44,602
#27 #18 AND #26 240
#28 #18 AND #26 AND [2006-2016]/py 177
```

## Cochrane Library search strategy

```
#1 MeSH descriptor: [Anemia, Sickle Cell] explode all trees 427
#2 MeSH descriptor: [Hemoglobin, Sickle] this term only 18
#3 ("sickle cell" or scd or "sc disease*"):ti,ab,kw 1227
#4 ('sickle anaemia' or 'sickle anemia'):ti,ab,kw 682
#5 ("hbs disease" or "hb ss disease"):ab,ti 0
#6 ("hemoglobin s" or "haemoglobin s"):ab,ti 29
#7 #1 or #2 or #3 or #4 or #5 or #6 1234
#8 MeSH descriptor: [Neonatal Screening] this term only 287
#9 ((neonat* or newborn*) near/5 screen*):ti,ab 448
#10 MeSH descriptor: [Mass Screening] this term only 4626
```

#11 MeSH descriptor: [Infant, Newborn] explode all trees 14307  
 #12 #10 and #11 123  
 #13 #8 or #9 or #12 630  
 #14 #7 and #13 18  
 #15 #7 and #13 Publication Year from 2006 to 2016 8

## Search results

Databases searched	Dates searched	Number of hits
Medline and Embase (Embase.com)	2006-08/03/2016	177
Cochrane Database Syst Rev (Cochrane Library)	2006-08/03/2016	0
CENTRAL (Cochrane Library)	2006-08/03/2016	4
HTA (Cochrane Library)	2006-08/03/2016	3
Cochrane Methodology (Cochrane Library)	2006-08/03/2016	1
<b>Total number of hits</b>		<b>185</b>
<b>Total number after de-duplication</b>		<b>179</b>
<b>Total number after first appraisal</b>		<b>49</b>

## 7. References

### Included after second pass sift (n=1)

1. Brosco, J. P., M. I. Seider and A. C. Dunn (2006). "Universal newborn screening and adverse medical outcomes: A historical note." *Mental Retardation and Developmental Disabilities Research Reviews* 12(4): 262-269.

### Included after first pass sift (n=49)

1. Amid, A. and I. Odame (2014). "Improving outcomes in children with sickle cell disease: Treatment considerations and strategies." *Pediatric Drugs* 16(4): 255-266.
2. Ardaillou, R. and J. Y. Le Gall (2006). "Generalized neonatal screening based on laboratory tests." *Bulletin de l'Académie nationale de médecine* 190(8): 1745-1759.
3. Ardaillou, R. and J. Y. Le Gall (2007). "Mass neonatal screening using biological testing." *Gynecologie Obstetrique Fertilité* 35(4): 367-374.
4. Badens, C. (2012). "Newborn screening for sickle cell disease: Current practice and perspectives." *International Journal of Laboratory Hematology* 34: 14.
5. Ballardini, E., A. Tarocco, M. Marsella, R. Bernardoni, G. Carandina, C. Melandri, G. Guerra, A. Patella, M. Zucchelli, A. Ferlini, S. Bigoni, A. Ravani, G. Garani and C. Borgna-Pignatti (2013). "Universal neonatal screening for sickle cell disease and other haemoglobinopathies in Ferrara, Italy." *Blood Transfusion* 11(2): 245-249.
6. Berthet, S., F. Monpoux, A. M. Soummer, E. Bérard, J. Sarles and C. Badens (2010). "Neonatal screening for sickle cell disease in Nice University Hospital: Review of 8 last years." *Archives de Pédiatrie* 17(12): 1652-1656.
7. Bombard, Y., F. A. Miller, R. Z. Hayeems, B. J. Wilson, J. C. Carroll, M. Paynter, J. Little, J. Allanson, J. P. Bytautas and P. Chakraborty (2012). "Health-care providers' views on pursuing reproductive benefit through newborn screening: The case of sickle cell disorders." *European Journal of Human Genetics* 20(5): 498-504.
8. Bowman, A., S. Taylor, P. Bora, H. Xu, L. Wells, L. Bowman, N. Barrett, R. Lottenberg, E. L. J. Clay, B. Pace, M. Lyon, R. Gibson and A. Kutlar (2015). "Demographic features of a mixed urban/rural adult sickle cell population: Opportunities and challenges for improving health care." *Blood* 126(23): 5594.
9. Brosco, J. P., M. I. Seider and A. C. Dunn (2006). "Universal newborn screening and adverse medical outcomes: A historical note." *Mental Retardation and Developmental Disabilities Research Reviews* 12(4): 262-269.
10. Cantero-Muñoz, P., G. Atienza, E. Dulín, T. Pàmols, R. Vizoso, R. Zubizarreta and M. López-García (2015). "Assessing newborn screening programmes: The Spanish experience and the role of the health technology assessment." *Journal of Perinatal Medicine* 43.
11. Cook, C., M. Smeltzer, N. Mortier, S. Kirk, J. Despotovic, R. Ware and J. Hankins (2012). "The clinical and laboratory spectrum of hemoglobin C disease." *Pediatric Blood and Cancer* 58(7): 1024.
12. Dick, M. C. (2008). "Standards for the management of sickle cell disease in children." *Archives of Disease in Childhood: Education and Practice Edition* 93(6): 169-176.

13. Giordano, P. C. (2013). "Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: Interpretation of results and pitfalls." *International Journal of Laboratory Hematology* 35(5): 465-479.
14. Hardie, R., L. King, R. Fraser and M. Reid (2009). "Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening." *Annals of Tropical Paediatrics* 29(3): 197-202.
15. Joiner, C. H. and L. Shook (2009). "Newborn screening for hemoglobinopathies: It's not just about sickle cell anemia." *American Journal of Hematology* 84(8): E130.
16. Kai, J., F. Ulph, T. Cullinan and N. Qureshi (2009). "Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: Qualitative study of experience and practice." *Health Technology Assessment* 13(57): 1-82.
17. Key, N. S., P. Connes and V. K. Derebail (2015). "Negative health implications of sickle cell trait in high income countries: From the football field to the laboratory." *British Journal of Haematology* 170(1): 5-14.
18. King, L., R. Fraser, M. Forbes, M. Grindley, S. Ali and M. Reid (2007). "Newborn sickle cell disease screening: The Jamaican experience (1995-2006)." *Journal of Medical Screening* 14(3): 117-122.
19. Kladny, B., A. Williams, E. A. Gettig and L. Krishnamurti (2009). "An evaluation of the impact of Newborn screening and genetic counseling on families with trait: A five year prospective study." *American Journal of Hematology* 84(8): E180.
20. Kladny, B., A. Williams, A. Gupta, E. A. Gettig and L. Krishnamurti (2011). "Genetic counseling following the detection of hemoglobinopathy trait on the newborn screen is well received, improves knowledge, and relieves anxiety." *Genetics in Medicine* 13(7): 658-661.
21. La Pean, A., J. L. Collins, S. A. Christopher, K. L. Eskra, S. J. Roedl, A. Tluczek and M. H. Farrell (2012). "A qualitative secondary evaluation of statewide follow-up interviews for abnormal newborn screening results for cystic fibrosis and sickle cell hemoglobinopathy." *Genetics in Medicine* 14(2): 207-214.
22. Lainé, A., J. Bardakdjian, F. Prunelle, F. E. Maroja, S. Quélet, R. Girot and A. Niakaté (2015). "The impact of screening sickle-cell carriers in the general population. A retrospective study in the Paris screening center." *Revue d'Epidemiologie et de Sante Publique* 63(2): 77-84.
23. Lê, P. Q., L. Dedeken, B. Gulbis, C. Vermylen, A. Vanderfaeillie, C. Heijmans, C. Devalck, S. Huybrechts, S. Benghiat, A. Efira, M. F. Dresse, S. Dupont and A. Ferster (2013). "Low sickle cell disease mortality in Belgium and benefit from hydroxyurea therapy." *Blood* 122(21).
24. Le, P. Q., A. Ferster, F. Vertongen, C. Vermylen, A. Vanderfaeillie, L. Dedeken, C. Heijmans, O. Ketelslegers, M. F. Dresse, A. Efira, C. Epalza and B. Gulbis (2010). "Sickle cell disease: From neonatal screening to clinical management." *Haematologica* 95: 423.
25. Lê, P. Q., A. Ferster, F. Vertongen, C. Vermylen, A. Vanderfaeillie, C. Heijmans, B. Nguyen, M. Ngalula Mijinga, L. Dedeken, D. Dufour, F. Ziereisen and B. Gulbis (2011). "Sickle cell disease data base: Neonatal screening or not? A Belgian experience." *Haematologica* 96: 303.
26. Le, P. Q., B. Gulbis, L. Dedeken, A. Vanderfaeillie, C. Heijmans, C. Vermylen, S. Huybrechts, C. Devalck, F. Cotton, B. C. Nguyen, F. Vertongen, M. Ngalula and A. Ferster (2012). "Newborn screening for sickle cell disease in Brussels, a program with an ongoing clinical

- outcome improvement." *Blood* 120(21).
27. Leahy, T. R., W. A. Gorman, J. Murphy and C. G. McMahon (2006). "Haemoglobinopathy screening in an maternity hospital." *Irish Medical Journal* 99(6).
  28. Lima, A. R. G., V. S. Ribeiro and D. I. Nicolau (2015). "Trends in mortality and hospital admissions of sickle cell disease patients before and after the newborn screening program in Maranhão, Brazil." *Revista Brasileira de Hematologia e Hemoterapia* 37(1): 12-16.
  29. Lin, K. and M. B. Barton (2007). Screening for hemoglobinopathies in newborns: reaffirmation update for the U.S. Preventive Services Task Force (Structured abstract). *Health Technology Assessment Database, Agency for Healthcare Research and Quality (AHRQ)*: 14.
  30. McGann, P. T., M. Muhongo, E. McGann, V. De Oliveira, B. Santos and R. E. Ware (2013). "Successful outcomes of an infant sickle cell clinic in Luanda, Angola." *Blood* 122(21).
  31. Meier, E. R. and J. L. Miller (2012). "Sickle cell disease in children." *Drugs* 72(7): 895-906.
  32. Moat, S. J., D. Rees, L. King, A. Ifederu, K. Harvey, K. Hall, G. Lloyd, C. Morrell and S. Hillier (2014). "Newborn blood spot screening for sickle cell disease by using tandem mass spectrometry: Implementation of a protocol to identify only the disease states of sickle cell disease." *Clinical Chemistry* 60(2): 373-380.
  33. Olujohungbe, A., J. Howard, A. Yardumian, L. Bennett, A. Nkohkwo, B. Davis, K. Ryan, S. Pancham and C. Chapman (2009). "Standards of care for Adult patients with Sickle Cell Disease in the United Kingdom." *British Journal of Haematology* 145: 24.
  34. Patel, N., H. Zhang, U. Zhuang, R. Redding-Lallinger, R. Luddy, A. Kutlar and F. Kutlar (2011). "Diagnostic challenge presented by "Hb F only" pattern in newborn screening for hemoglobinopathies: Approach to accurate diagnosis." *American Journal of Hematology* 86(10): E2.
  35. Peters, M., K. Fijnvandraat, X. W. Van Den Tweel, F. G. Garre, P. C. Giordano, J. P. Van Wouwe, R. R. Pereira and P. H. Verkerk (2010). "One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening." *Archives of Disease in Childhood* 95(10): 822-825.
  36. Priddee, N. R., L. M. McIlwaine, S. Smith, E. A. Chalmers, G. Marron and B. J. Robertson (2014). "Prevalence of major haemoglobinopathies in Scotland: Analysis of newborn screening programme." *British Journal of Haematology* 165: 87.
  37. Queiro Verdes, T. (2013). Neonatal screening of sickle cell anemia (Structured abstract). *Health Technology Assessment Database, Galician Agency for Health Technology Assessment (AVALIA-T)*.
  38. Quoc Le, P., B. Gulbis, L. Dedeken, A. Vanderfaeillie, C. Heijmans, C. Vermynen, S. Huybrechts, C. Devalck, F. Cotton, B. Nguyen, F. Vertongen, M. Mujinga and A. Ferster (2013). "Newborn screening for sickle cell disease in Brussels, a program with an ongoing clinical outcome improvement." *Haematologica* 98: 174.
  39. Rodriguez-Moldes, B., A. J. Carbajo, B. Sanchez, M. Fernandez, M. Gari, M. C. Fernandez, J. Alvarez, A. Garcia and E. Cela (2015). "Primary care follow-up of newborns with sickle cell disease detected in neonatal screening in the Community of Madrid." *Anales de Pediatría* 82(4): 222-227.
  40. Roseff, S. D. (2009). "Sickle cell disease: A review." *Immunohematology* 25(2): 67-74.

41. Schultz, C. L., T. Tchume-Johnson, T. Jackson, H. Enniful-Eghan, M. Schapira and K. Smith-Whitley (2014). "Reproductive decisions in families affected by sickle cell disease." *Blood* 124(21).
42. Silva, C. D. A., L. B. Baldim, G. C. Nhoncanse, I. D. F. Estevão and D. G. Melo (2015). "Neonatal screening for hemoglobinopathies in São Carlos, São Paulo, Brazil: Analysis of a series of cases." *Revista Paulista de Pediatria* 33(1): 19-27.
43. Sobota, A., V. Sabharwal, G. Fonebi and M. Steinberg (2015). "How we prevent and manage infection in sickle cell disease." *British Journal of Haematology* 170(6): 757-767.
44. Sutton, D., R. Gregg, G. Lowe, S. Pancham, N. Phillips and C. Wright (2011). "Primary care vaccination and antibiotic prophylaxis in patients with sickle cell disease: Auditing NCEPOD recommendations." *British Journal of Haematology* 153: 41-42.
45. Telfer, P. T. (2011). "Management of sickle cell disease: Out-patient and community aspects." *Paediatrics and Child Health* 21(8): 357-362.
46. Telfer, P. T. (2015). "Management of sickle cell disease: Out-patient and community aspects." *Paediatrics and Child Health (United Kingdom)* 25(8): 375-380.
47. Tuaño, K. R., E. E. Ezeanolue, A. Hunt, S. Shahani and W. Whitten-Shurney (2013). "State health departments handling of sickle cell trait results identified through the newborn screening programs." *Journal of Investigative Medicine* 61(1): 165.
48. Vansenne, F., C. A. J. M. De Borgie, M. Legdeur, M. O. Spauwen and M. Peters (2011). "Providing genetic risk information to parents of newborns with sickle cell trait: Role of the general practitioner in neonatal screening." *Genetic Testing and Molecular Biomarkers* 15(10): 671-675.
49. Ware, R. E. (2013). "Hydroxycarbamide: Clinical aspects." *Comptes Rendus - Biologies* 336(3): 177-182.

## Full search results (n=179)

1. Acharya, K., C. W. Lang and L. F. Ross (2009). "A pilot study to explore knowledge, attitudes, and beliefs about sickle cell trait and disease." *Journal of the National Medical Association* 101(11): 1163-1172.
2. Akodu, S. O., I. N. Diaku-Akinwumi and O. F. Njokanma (2013). "Age at diagnosis of sickle cell anaemia in Lagos, Nigeria." *Mediterranean Journal of Hematology and Infectious Diseases* 5(1).
3. Al Aqeel, A. I. (2011). "Personalized translational medicine in the developing world, and knowledge-based economy." *HUGO Journal* 5(1): 75.
4. Al-Alawi, M. and N. Sarhan (2014). "Prevalence of anemia among nine-month-old infants attending primary care in Bahrain." *Journal of the Bahrain Medical Society* 25(1): 29-32.
5. Aloni, M. N. and L. Nkee (2014). "Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: A sickle cell center experience." *Hemoglobin* 38(3): 196-200.
6. Al-Qurashi, M. M., M. I. El-Mouzan, A. S. Al-Herbish, A. A. Al-Salloum and A. A. Al-Omar (2008). "The prevalence of sickle cell disease in Saudi children and adolescents. A community-based survey." *Saudi Medical Journal* 29(10): 1480-1483.

7. Alvear, C. C., M. Barboza, M. Viola, C. Moneriz and L. M. Araque (2012). "Pilot study of hemoglobinopathies in newborns of the Rafael Calvo maternity clinic of Cartagena, Colombia." *Colombia Medica* 43(3): 196-199.
8. Amid, A. and I. Odame (2014). "Improving outcomes in children with sickle cell disease: Treatment considerations and strategies." *Pediatric Drugs* 16(4): 255-266.
9. Ansong, D., A. O. Akoto, D. Ocloo and K. Ohene-Frempong (2013). "Sickle cell disease: Management options and challenges in developing countries." *Mediterranean Journal of Hematology and Infectious Diseases* 5(1): 1-6.
10. Araújo, A., G. Drelichman, R. D. Caçado, N. Watman, S. M. M. Magalhães, M. Duhalde, J. Marfil, A. Feliú, L. Clementina, A. L. Ballesteros, M. di Stefano, I. Angulo, A. Fattori, S. Figueiredo, J. Friedrich, F. Pereira, J. Peña, A. Barrero, S. Guerrero, G. Gutiérrez-Espíndola, V. S. Rojas, J. Soto, J. Boyd, R. Joly, M. Sergio, A. M. de Soyano, O. Pérez-Báñez and Z. Plumacher (2009). "Management of transfusional iron overload in Latin America: Current outlook and expert panel recommendations." *Hematology* 14(1): 22-32.
11. Ardaillou, R. and J. Y. Le Gall (2006). "Generalized neonatal screening based on laboratory tests." *Bulletin de l'Académie nationale de médecine* 190(8): 1745-1759.
12. Ardaillou, R. and J. Y. Le Gall (2007). "Mass neonatal screening using biological testing." *Gynecologie Obstetrique Fertilité* 35(4): 367-374.
13. Argent, E., P. Emder, P. Monagle, D. Mowat, T. Petterson, S. Russell, R. Sachdev, C. Stone and D. S. Ziegler (2012). "Australian paediatric surveillance unit study of haemoglobinopathies in Australian children." *Journal of Paediatrics and Child Health* 48(4): 356-360.
14. Badens, C. (2012). "Newborn screening for sickle cell disease: Current practice and perspectives." *International Journal of Laboratory Hematology* 34: 14.
15. Ballardini, E., A. Tarocco, R. Burnelli and C. Borgna (2011). "Universal newborn screening for sickle cell disease and other hemoglobinopathies in Ferrara." *Haematologica* 96: 104-105.
16. Ballardini, E., A. Tarocco, M. Marsella, R. Bernardoni, G. Carandina, C. Melandri, G. Guerra, A. Patella, M. Zucchelli, A. Ferlini, S. Bigoni, A. Ravani, G. Garani and C. Borgna-Pignatti (2013). "Universal neonatal screening for sickle cell disease and other haemoglobinopathies in Ferrara, Italy." *Blood Transfusion* 11(2): 245-249.
17. Bello, A. C. (2013). "Hemoglobinopathies of difficult diagnosis. Case reports from a main referral pediatric hospital in Venezuela." *Blood* 122(21).
18. Berthet, S., F. Monpoux, A. M. Soummer, E. Bérard, J. Sarles and C. Badens (2010). "Neonatal screening for sickle cell disease in Nice University Hospital: Review of 8 last years." *Archives de Pédiatrie* 17(12): 1652-1656.
19. Bombard, Y., F. A. Miller, R. Z. Hayeems, B. J. Wilson, J. C. Carroll, M. Paynter, J. Little, J. Allanson, J. P. Bytautas and P. Chakraborty (2012). "Health-care providers' views on pursuing reproductive benefit through newborn screening: The case of sickle cell disorders." *European Journal of Human Genetics* 20(5): 498-504.
20. Bowman, A., S. Taylor, P. Bora, H. Xu, L. Wells, L. Bowman, N. Barrett, R. Lottenberg, E. L. J. Clay, B. Pace, M. Lyon, R. Gibson and A. Kutlar (2015). "Demographic features of a mixed urban/rural adult sickle cell population: Opportunities and challenges for improving health care." *Blood* 126(23): 5594.

21. Brosco, J. P., M. I. Seider and A. C. Dunn (2006). "Universal newborn screening and adverse medical outcomes: A historical note." *Mental Retardation and Developmental Disabilities Research Reviews* 12(4): 262-269.
22. Burke, W., B. Tarini, N. A. Press and J. P. Evans (2011). "Genetic screening." *Epidemiologic Reviews* 33(1): 148-164.
23. Bush, A. (2014). "Paediatric pulmonology: Year in review." *Pediatric Pulmonology* 49: S2-S3.
24. Camp, K. M., M. A. Lloyd-Puryear and K. L. Huntington (2012). "Nutritional treatment for inborn errors of metabolism: Indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example." *Molecular Genetics and Metabolism* 107(1-2): 3-9.
25. Campbell, A., K. O. Bonsu, P. Ross, P. Gorodinsky, T. Kpadenou, S. Wilson and O. Rodrigues (2012). "Early diagnosis patterns amongst Ghanaian twins and siblings with sickle cell disease." *American Journal of Hematology* 87(7): E24.
26. Cantero-Muñoz, P., G. Atienza, E. Dulín, T. Pàmols, R. Vizoso, R. Zubizarreta and M. López-García (2015). "Assessing newborn screening programmes: The Spanish experience and the role of the health technology assessment." *Journal of Perinatal Medicine* 43.
27. Cela De Julián, E., E. Dulín Íñiguez, M. Guerrero Soler, M. Arranz Leirado, P. Galarón García, C. Beléndez Bieler, J. M. Bellón Cano, M. García Arias and A. Cantalejo López (2007). "Evaluation of systematic neonatal screening for sickle cell diseases in Madrid three years after its introduction." *Anales de Pediatría* 66(4): 382-386.
28. Chakravorty, S. and T. N. Williams (2015). "Sickle cell disease: A neglected chronic disease of increasing global health importance." *Archives of Disease in Childhood* 100(1): 48-53.
29. Colah, R. B., A. C. Gorakshakar and A. H. Nadkarni (2011). "Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: Experiences from india." *Indian Journal of Medical Research* 134(10): 552-560.
30. Cook, C., M. Smeltzer, N. Mortier, S. Kirk, J. Despotovic, R. Ware and J. Hankins (2012). "The clinical and laboratory spectrum of hemoglobin C disease." *Pediatric Blood and Cancer* 58(7): 1024.
31. Dalili, S., S. M. Rezvani, H. Dalili, Z. M. Amiri, H. Mohammadi, S. A. Kesh, M. H. Novin, A. Medghalchi and H. Gholamnezhad (2014). "Congenital hypothyroidism: Etiology and growth-development outcome." *Acta Medica Iranica* 52(10): 752-756.
32. Dampier, C., E. Ely, L. Aertker, D. Brodecki, K. Kesler and M. Stuart (2010). "Pain in infants and young children with sickle cell disease-a prospective longitudinal analysis." *Blood* 116(21).
33. De Montalembert, M. (2008). "Management of sickle cell disease." *BMJ* 337(7670): 626-630.
34. De Montalembert, M. and I. Roberts (2010). "Sickle cell disease: Primum non nocere (first do no harm)." *Haematologica* 95(1): 4-6.
35. De Montalembert, M. and L. Tshilolo (2007). "Is therapeutic progress in the management of sickle cell disease applicable in sub-Saharan Africa?" *Médecine tropicale : revue du Corps de santé colonial* 67(6): 612-616.
36. Dick, M. C. (2008). "Standards for the management of sickle cell disease in children." *Archives of Disease in Childhood: Education and Practice Edition* 93(6): 169-176.

37. Dixit, S., P. Sahu, S. K. Kar and S. Negi (2015). "Identification of the hot-spot areas for sickle cell disease using cord blood screening at a district hospital: an Indian perspective." *Journal of Community Genetics* 6(4): 383-387.
38. Douglas, C. M. W., C. G. van El, A. Faulkner and M. C. Cornel (2012). "Governing biological material at the intersection of care and research: The use of dried blood spots for biobanking." *Croatian Medical Journal* 53(4): 390-397.
39. Doulton, D. M. (2009). "Transition: From cradle to commencement." *American Journal of Hematology* 84(8): E111.
40. Downing, G. J., A. E. Zuckerman, C. Coon and M. A. Lloyd-Puryear (2010). "Enhancing the Quality and Efficiency of Newborn Screening Programs Through the Use of Health Information Technology." *Seminars in Perinatology* 34(2): 156-162.
41. Edwin, A. K., F. Edwin and V. Etwire (2011). "Controlling sickle cell disease in Ghana - Ethics and options." *Pan African Medical Journal* 10.
42. Esparza, L., B. Jones, I. Sulapas, E. Cobos and J. J. Mitchell (2014). "Don't get fooled by the screen." *Clinical Journal of Sport Medicine* 24(2): 177.
43. Farrell, M. H., S. A. Christopher, A. L. P. Kirschner, S. J. Roedl, F. O. O'Tool, N. Y. Ahmad and P. M. Farrell (2014) "Improving the quality of physician communication with rapid-throughput analysis and report cards." *Patient education and counseling* 97, 248-255 DOI: 10.1016/j.pec.2014.07.028.
44. Frömmel, C., A. Brose, J. Klein, O. Blankenstein and S. Lobitz (2014). "Newborn Screening for Sickle Cell Disease: Technical and Legal Aspects of a German Pilot Study with 38,220 Participants." *BioMed Research International* 2014.
45. Galadanci, N., B. J. Wudil, T. M. Balogun, G. O. Ogunrinde, A. Akinsulie, F. Hasan-hanga, A. S. Mohammed, M. O. Kehinde, J. A. Olaniyi, I. N. Diaku-akinwumi, B. J. Brown, S. Adeleke, O. E. Nnodu, I. Emodi, S. Ahmed, A. O. Osegbue, N. Akinola, H. I. O. Opara, S. A. Adegoke, J. Aneke and A. D. Adekile (2014). "Current sickle cell disease management practices in Nigeria." *International Health* 6(1): 23-28.
46. Galvin-Parton, P., G. Goldstein, B. Ozturk and J. Weiss (2012). "Pediatric genetics: Family, patient and clinical staff evaluation of implementing a personal electronic health record for infants who test positive on the state newborn screen." *Molecular Genetics and Metabolism* 105(3): 320.
47. Ghosh, K., R. Colah, M. Manglani, V. P. Choudhry, I. Verma, N. Madan, R. Saxena, D. Jain, N. Marwaha, R. Das, D. Mohanty, R. Choudhary, S. Agarwal, M. Ghosh and C. Ross (2014). "Guidelines for screening, diagnosis and management of Hemoglobinopathies." *Indian Journal of Human Genetics* 20(2): 101-119.
48. Ghosh, K., R. B. Colah and M. B. Mukherjee (2015). "Haemoglobinopathies in tribal populations of India." *Indian Journal of Medical Research* 141(May): 505-508.
49. Gibbons, G. H., U. K. A. Sampson, N. L. Cook and G. A. Mensah (2015). "NHLBI perspectives on the growth of heart, lung, blood and sleep conditions in Africa: Global and domestic insights, challenges and opportunities." *Cardiovascular Journal of Africa* 26(2): S18-S20.
50. Giordano, P. C. (2013). "Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: Interpretation of results and pitfalls." *International Journal of Laboratory Hematology* 35(5): 465-479.

51. Giordano, P. C., C. L. Hartevelde and E. Bakker (2014). "Genetic epidemiology and preventive healthcare in multiethnic societies: The hemoglobinopathies." *International Journal of Environmental Research and Public Health* 11(6): 6136-6146.
52. Gonzales, J. L. (2011). "Genetic testing and newborn screening." *Pediatrics in Review* 32(11): 490-493.
53. Grigorescu, V. (2009). "Using Pregnancy Risk Assessment Monitoring System (PRAMS) for different public health programs - Lessons learned." *American Journal of Hematology* 84(8): E135.
54. Grigorescu, V., M. J. Kleyn, S. J. Korzeniewski, W. I. Young and W. Whitten-Shurney (2010). "Newborn Screening Follow-Up Within the Lifespan Context. Michigan's Experience." *American Journal of Preventive Medicine* 38(4 SUPPL.): S522-S527.
55. Hajer, S., T. Neila, H. F. Sondess, O. Fekria, A. Nabila, K. Mahbouba, D. Melika, O. Faïda, B. Amina, B. Raja, R. Hedi, M. Sadok, K. Naima, F. Slaheddine and M. Taieb (2012). "A lower-cost protocol for sickle cell disease neonatal screening in Tunisia." *Annals of Saudi Medicine* 32(1): 49-52.
56. Hardie, R., L. King, R. Fraser and M. Reid (2009). "Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening." *Annals of Tropical Paediatrics* 29(3): 197-202.
57. Hartshorne, C. F., B. Canty, K. Quirolo, J. Earl and M. Treadwell (2011). "Genetic counseling for everyone: Increasing availability in a sickle cell network." *American Journal of Hematology* 86(10): E29-E30.
58. Hassell, K. L. (2010). "Population Estimates of Sickle Cell Disease in the U.S." *American Journal of Preventive Medicine* 38(4 SUPPL.): S512-S521.
59. Heijboer, H., X. W. Van Den Tweel, K. Fijnvandraat and M. Peters (2007). "Recognition of children with sickle cell disease in the Netherlands." *Nederlands Tijdschrift voor Geneeskunde* 151(45): 2498-2501.
60. Heimlich, J. B., G. Chipoka, P. Kamthunzi, Y. D. Fedoriw, N. S. Key, K. I. Ataga and S. Gopal (2015). "Establishing sickle cell diagnostics and characterizing a pediatric sickle cell disease cohort in Malawi." *Blood* 126(23): 2070.
61. Hendricks, M., F. Desai, A. Davidson and B. Files (2010). "Recurrent acute splenic sequestration in a known double heterozygote (HB S-beta thalassemia) necessitating elective laparoscopic splenectomy." *American Journal of Hematology* 85(8): E54.
62. Hoots, W. K. and S. B. Shurin (2012). "Future directions of sickle cell disease research: The NIH perspective." *Pediatric Blood and Cancer* 59(2): 353-357.
63. Jackson, J. M., K. S. Crider and R. S. Olney (2010). Population-based surveillance for rare congenital and inherited disorders: Models and challenges. *686*: 133-150.
64. Joiner, C. H. and L. Shook (2009). "Newborn screening for hemoglobinopathies: It's not just about sickle cell anemia." *American Journal of Hematology* 84(8): E130.
65. Joly, P., C. Pondarré, C. Bardel, A. Francina and C. Martin (2012). "The alpha-globin genotype does not influence sickle cell disease severity in a retrospective cross-validation study of the pediatric severity score." *European Journal of Haematology* 88(1): 61-67.

66. Joyanes, B., M. Moro, P. Ropero, O. Briceño, E. Dulín and A. Villegas (2006). "Screening of hemoglobinopathies in a cohort of newborns in Madrid." *Medicina Clinica* 126(8): 290-292.
67. Kadima, B. T., J. L. Gini Ehungu, R. M. Ngiyulu, P. M. Ekulu and M. N. Aloni (2015). "High rate of sickle cell anaemia in Sub-Saharan Africa underlines the need to screen all children with severe anaemia for the disease." *Acta Paediatrica, International Journal of Paediatrics* 104(12): 1269-1273.
68. Kai, J., F. Ulph, T. Cullinan and N. Qureshi (2009). "Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: Qualitative study of experience and practice." *Health Technology Assessment* 13(57): 1-82.
69. Kanter, J. and R. Kruse-Jarres (2013). "Management of sickle cell disease from childhood through adulthood." *Blood Reviews* 27(6): 279-287.
70. Kavanagh, P. L., P. G. Sprinz, S. R. Vinci, H. Bauchner and C. J. Wang (2011). "Management of children with sickle cell disease: A comprehensive review of the literature." *Pediatrics* 128(6): e1552-e1574.
71. Kaye, C. I., G. B. Schaefer, M. J. Bull, G. M. Enns, J. R. Gruen, J. H. Hersh, N. J. Mendelsohn and H. M. Saal (2006). "Introduction to the newborn screening fact sheets." *Pediatrics* 118(3): 1304-1312.
72. Kaye, C. I., G. B. Schaefer, M. J. Bull, G. M. Enns, J. R. Gruen, J. H. Hersh, N. J. Mendelsohn and H. M. Saal (2006). "Newborn screening fact sheets." *Pediatrics* 118(3): e934-e963.
73. Key, N. S., P. Connes and V. K. Derebail (2015). "Negative health implications of sickle cell trait in high income countries: From the football field to the laboratory." *British Journal of Haematology* 170(1): 5-14.
74. Kharrazi, M., S. Young, S. Lessing, T. Bishop, G. Helmer and F. Lorey (2012). "California cystic fibrosis newborn screening: Review of the first 4 years." *Pediatric Pulmonology* 47: 377.
75. Khattab, A. D., B. Rawlings and I. S. Ali (2006). "Care of patients with haemoglobin abnormalities: nursing management." *British journal of nursing (Mark Allen Publishing)* 15(19): 1057-1062.
76. King, L., R. Fraser, M. Forbes, M. Grindley, S. Ali and M. Reid (2007). "Newborn sickle cell disease screening: The Jamaican experience (1995-2006)." *Journal of Medical Screening* 14(3): 117-122.
77. Kingsmore, S. F., J. D. Lantos, D. L. Dinwiddie, N. A. Miller, S. E. Soden, E. G. Farrow and C. J. Saunders (2012). "Next-generation community genetics for low- and middle-income countries." *Genome Medicine* 4(3).
78. Kladny, B., M. Campbell and L. Krishnamurti (2010). "Complex trait identification: Finding answers and counseling families." *American Journal of Hematology* 85(8): E53.
79. Kladny, B., A. Williams, A. Aloe and L. Krishnamurti (2010). "Visibility, flexibility, and stability enhance sickle cell disease and trait treatment in western pennsylvania." *American Journal of Hematology* 85(8): E50.
80. Kladny, B., A. Williams, E. A. Gettig and L. Krishnamurti (2009). "An evaluation of the impact of Newborn screening and genetic counseling on families with trait: A five year prospective study." *American Journal of Hematology* 84(8): E180.

81. Kladny, B., A. Williams, A. Gupta, E. A. Gettig and L. Krishnamurti (2011). "Genetic counseling following the detection of hemoglobinopathy trait on the newborn screen is well received, improves knowledge, and relieves anxiety." *Genetics in Medicine* 13(7): 658-661.
82. Kuehn, B. M. (2013). "After 50 years, newborn screening continues to yield public health gains." *JAMA - Journal of the American Medical Association* 309(12): 1215-1217.
83. La Pean, A., J. L. Collins, S. A. Christopher, K. L. Eskra, S. J. Roedl, A. Tluczek and M. H. Farrell (2012). "A qualitative secondary evaluation of statewide follow-up interviews for abnormal newborn screening results for cystic fibrosis and sickle cell hemoglobinopathy." *Genetics in Medicine* 14(2): 207-214.
84. Lainé, A., J. Bardakdjian, F. Prunelle, F. E. Maroja, S. Quélet, R. Girot and A. Niakaté (2015). "The impact of screening sickle-cell carriers in the general population. A retrospective study in the Paris screening center." *Revue d'Epidemiologie et de Sante Publique* 63(2): 77-84.
85. Lang, C. W., A. P. Stark, K. Acharya and L. F. Ross (2009). "Maternal knowledge and attitudes about newborn screening for sickle cell disease and cystic fibrosis." *American Journal of Medical Genetics, Part A* 149(11): 2424-2429.
86. Lê, P. Q., L. Dedeken, B. Gulbis, C. Vermylen, A. Vanderfaeillie, C. Heijmans, C. Devalck, S. Huybrechts, S. Benghiat, A. Efira, M. F. Dresse, S. Dupont and A. Ferster (2013). "Low sickle cell disease mortality in Belgium and benefit from hydroxyurea therapy." *Blood* 122(21).
87. Le, P. Q., A. Ferster, F. Vertongen, C. Vermylen, A. Vanderfaeillie, L. Dedeken, C. Heijmans, O. Ketelslegers, M. F. Dresse, A. Efira, C. Epalza and B. Gulbis (2010). "Sickle cell disease: From neonatal screening to clinical management." *Haematologica* 95: 423.
88. Lê, P. Q., A. Ferster, F. Vetongen, C. Vermylen, A. Vanderfaeillie, C. Heijmans, B. Nguyen, M. Ngalula Mijinga, L. Dedeken, D. Dufour, F. Ziereisen and B. Gulbis (2011). "Sickle cell disease data base: Neonatal screening or not? A Belgian experience." *Haematologica* 96: 303.
89. Le, P. Q., B. Gulbis, L. Dedeken, A. Vanderfaeillie, C. Heijmans, C. Vermylen, S. Huybrechts, C. Devalck, F. Cotton, B. C. Nguyen, F. Vertongen, M. Ngalula and A. Ferster (2012). "Newborn screening for sickle cell disease in Brussels, a program with an ongoing clinical outcome improvement." *Blood* 120(21).
90. Leahy, T. R., W. A. Gorman, J. Murphy and C. G. McMahon (2006). "Haemoglobinopathy screening in an maternity hospital." *Irish Medical Journal* 99(6).
91. Leão, L. L. and M. J. B. De Aguiar (2008). "Newborn screening: What pediatricians should know." *Jornal de Pediatria* 84(4 SUPPL.): S80-S90.
92. Leite, A. C. C., C. M. Silva, R. Azevedo, P. Moura, R. V. C. Oliveira and C. L. Lobo (2009). "Transcranial doppler (TCD) and neurological manifestations in Brazilian pediatric patients with SCD." *Blood* 114(22).
93. Levy, H. L. (2014). "Newborn screening-the first 50 years." *Molecular Genetics and Metabolism* 111(3): 225.
94. Lima, A. R. G., V. S. Ribeiro and D. I. Nicolau (2015). "Trends in mortality and hospital admissions of sickle cell disease patients before and after the newborn screening program in Maranhão, Brazil." *Revista Brasileira de Hematologia e Hemoterapia* 37(1): 12-16.
95. Lin, K. and M. B. Barton (2007). Screening for hemoglobinopathies in newborns: reaffirmation update for the U.S. Preventive Services Task Force (Structured abstract). *Health Technology*

Assessment Database, Agency for Healthcare Research and Quality (AHRQ): 14.

96. Loeber, J. G. (2007). "Neonatal screening in Europe; the situation in 2004." *Journal of Inherited Metabolic Disease* 30(4): 430-438.
97. Makani, J., S. E. Cox, D. Soka, A. N. Komba, P. Magesa, S. Rwezaula, E. Meda, J. Mgaya, G. Fegan, F. Kirkham, K. Marsh, C. R. C. J. Newton and D. J. Roberts (2011). "Mortality in sickle cell anaemia in Africa: Rates and risk factors from a prospective cohort study in Tanzania." *British Journal of Haematology* 153: 27.
98. Makani, J., S. E. Cox, D. Soka, A. N. Komba, J. Oruo, H. Mwamtemi, P. Magesa, S. Rwezaula, E. Meda, J. Mgaya, B. Lowe, D. Muturi, D. J. Roberts, T. N. Williams, K. Pallangyo, J. Kitundu, G. Fegan, F. J. Kirkham, K. Marsh and C. R. Newton (2011). "Mortality in sickle cell anemia in africa: A prospective cohort study in Tanzania." *PLoS ONE* 6(2).
99. Mathias, M. D., S. Zhang, Z. R. Rogers, G. R. Buchanan, A. C. Nero and T. L. McCavit (2014). "Survival into adulthood in sickle cell disease from the dallas newborn cohort." *Blood* 124(21).
100. McCavit, T. L. (2012). "Sickle cell disease." *Pediatrics in Review* 33(5): 195-206.
101. McGann, P. T., V. De Oliveira, T. A. Howard, S. E. Kirk, E. N. Hansbury, M. G. Ferris and R. E. Ware (2012). "Cost and reliability of two methods of hemoglobin identification for sickle cell newborn screening in the republic of angola." *Blood* 120(21).
102. McGann, P. T., M. Muhongo, E. McGann, V. De Oliveira, B. Santos and R. E. Ware (2013). "Successful outcomes of an infant sickle cell clinic in Luanda, Angola." *Blood* 122(21).
103. McGann, P. T., A. C. Nero and R. E. Ware (2013). "Current management of sickle cell anemia." *Cold Spring Harbor Perspectives in Medicine* 3(8).
104. McWalter, K. M., E. M. White, D. K. Hayes and S. M. Au (2011). "Hemoglobinopathy newborn screening knowledge of physicians." *American Journal of Preventive Medicine* 41(6 SUPPL.4): S384-S389.
105. Mehta, M. (2015). "Genetic screening for birth defects." *Journal of Perinatal Medicine* 43.
106. Meier, E. R. and J. L. Miller (2012). "Sickle cell disease in children." *Drugs* 72(7): 895-906.
107. Mikles, B., M. Bhatia, S. O. Oyeku and N. S. Green (2012). "Hematology provider perspectives on hematopoietic stem cell transplantation for pediatric sickle cell disease." *Blood* 120(21).
108. Moat, S. J., D. Rees, L. King, A. Ifederu, K. Harvey, K. Hall, G. Lloyd, C. Morrell and S. Hillier (2014). "Newborn blood spot screening for sickle cell disease by using tandem mass spectrometry: Implementation of a protocol to identify only the disease states of sickle cell disease." *Clinical Chemistry* 60(2): 373-380.
109. Mohanty, D. (2014). "A century after discovery of sickle cell disease: Keeping hope alive!" *Indian Journal of Medical Research* 139(JUN): 793-795.
110. Mohanty, D. and K. Das (2011). "Genetic counselling in tribals in India." *Indian Journal of Medical Research* 134(10): 561-571.
111. Mohanty, D., K. Das, K. Misra and P. Investigator (2011). "Newborn screening for sickle cell disease & congenital hypothyroidism in western Orissa." *Indian Journal of Hematology and Blood Transfusion* 27(4): 278.

112. Moraes, M. H. P., L. S. Santos, P. G. Moura and C. L. C. Lobo (2009). "SOCIAL Services IN newborn screening." *American Journal of Hematology* 84(8): E145-E146.
113. Muhammed-Ighile, F. and E. M. Novelli (2012). "Living with sickle cell disease in Nigeria." *American Journal of Hematology* 87(7): E22.
114. Mutesa, L., F. Boemer, L. Ngendahayo, S. Rulisa, E. K. Rusingiza, N. Cwinya-Ay, D. Mazina, P. C. Kariyo, V. Bours and R. Schoos (2007). "Neonatal screening for sickle cell disease in Central Africa: A study of 1825 newborns with a new enzyme-linked immunosorbent assay test." *Journal of Medical Screening* 14(3): 113-116.
115. Nason, C. S., C. B. Mapp and B. Wheatley (2009). "Building a medical home for those with sickle cell disease: Learning from the ANSCAPE primary care improvement process model for Federally Qualified Health Centers." *American Journal of Hematology* 84(8): E154-E155.
116. Ndila, C., E. Bauni, V. Nyirongo, G. Mochamah, A. Makazi, P. Kosgei, G. Nyutu, A. Macharia, S. Kapesa, P. Byass and T. N. Williams (2014). "Verbal autopsy as a tool for identifying children dying of sickle cell disease: A validation study conducted in Kilifi district, Kenya." *BMC Medicine* 12(1).
117. Nwaneri, M. O., A. Osei-Akoto and B. J. Brabin (2009). "External evaluation of Newborn screening for sickle cell disease in Ghana." *American Journal of Hematology* 84(8): E161-E162.
118. Obaro, S., Y. Daniel, J. Lawson, J. Dada, U. Essen, W. Wei, A. Akindele, K. Ibrahim, G. Olanipekun, E. Obe, T. Ajose and B. Inusa (2012). "Sickle cell anaemia in Nigerian children: Parental knowledge and laboratory results." *Haematologica* 97: 702.
119. Odame, I. (2010). "Developing a Global Agenda for Sickle Cell Disease. Report of an International Symposium and Workshop in Cotonou, Republic of Benin." *American Journal of Preventive Medicine* 38(4 SUPPL.): S571-S575.
120. Odunvbun, M. E., A. A. Okolo and C. M. Rahimy (2008). "Newborn screening for sickle cell disease in a Nigerian hospital." *Public Health* 122(10): 1111-1116.
121. O'Leary, J. D., I. Odame, C. Pehora, P. Chakraborty and M. W. Crawford (2013). "Effectiveness of preoperative screening for sickle cell disease in a population with a newborn screening program: A cohort study." *Canadian Journal of Anesthesia* 60(1): 54-59.
122. Olujohungbe, A., J. Howard, A. Yardumian, L. Bennett, A. Nkohkwo, B. Davis, K. Ryan, S. Panchar and C. Chapman (2009). "Standards of care for Adult patients with Sickle Cell Disease in the United Kingdom." *British Journal of Haematology* 145: 24.
123. O'Meara, M. and M. Allford (2010). "Anaesthesia for patients with sickle cell and other haemoglobinopathies." *Anaesthesia and Intensive Care Medicine* 11(6): 242-243.
124. Oyeku, S. O., H. A. Feldman, K. Ryan, S. Muret-Wagstaff and E. J. Neufeld (2010) "Primary care clinicians' knowledge and confidence about newborn screening for sickle cell disease: randomized assessment of educational strategies." *Journal of the National Medical Association* 102, 676-682.
125. Patel, N., H. Zhang, U. Zhuang, R. Redding-Lallinger, R. Luddy, A. Kutlar and F. Kutlar (2011). "Diagnostic challenge presented by "Hb F only" pattern in newborn screening for hemoglobinopathies: Approach to accurate diagnosis." *American Journal of Hematology* 86(10): E2.
126. Paul Starr, S. (2012). "Genetic blood disorders: Questions you need to ask." *Journal of Family*

Practice 61(1): 30-37.

127. Perry, L. L., L. D. Drawhorn, V. Beckley and K. Saving (2009). "Education through collaborative efforts." *American Journal of Hematology* 84(8): E112.
128. Peters, M., K. Fijnvandraat, X. W. Van Den Tweel, F. G. Garre, P. C. Giordano, J. P. Van Wouwe, R. R. Pereira and P. H. Verkerk (2010). "One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening." *Archives of Disease in Childhood* 95(10): 822-825.
129. Prabhakar, H., C. Haywood Jr and R. Molokie (2010). "Sickle cell disease in the United States: Looking back and forward at 100 years of progress in management and survival." *American Journal of Hematology* 85(5): 346-353.
130. Priddee, N. R., L. M. McIlwaine, S. Smith, E. A. Chalmers, G. Marron and B. J. Robertson (2014). "Prevalence of major haemoglobinopathies in Scotland: Analysis of newborn screening programme." *British Journal of Haematology* 165: 87.
131. Queiro Verdes, T. (2013). Neonatal screening of sickle cell anemia (Structured abstract). Health Technology Assessment Database, Galician Agency for Health Technology Assessment (AVALIA-T).
132. Quimby, K. R., S. Moe, I. Sealy, C. Nicholls, I. R. Hambleton and R. C. Landis (2014). "Clinical findings associated with homozygous sickle cell disease in the Barbadian population--do we need a national SCD registry?" *BMC research notes* 7: 102.
133. Quinn, C. T. (2013). "Sickle cell disease in childhood. from newborn screening through transition to adult medical care." *Pediatric Clinics of North America* 60(6): 1363-1381.
134. Quoc Le, P., B. Gulbis, L. Dedeken, A. Vanderfaeillie, C. Heijmans, C. Vermylen, S. Huybrechts, C. Devalck, F. Cotton, B. Nguyen, F. Vertongen, M. Mujinga and A. Ferster (2013). "Newborn screening for sickle cell disease in Brussels, a program with an ongoing clinical outcome improvement." *Haematologica* 98: 174.
135. Reeves, S. L., K. J. Dombkowski, H. Fullerton, T. Braun and L. D. Lisabeth (2014). "The association of neighborhood and transcranial doppler screening among children with sickle cell disease." *Stroke* 45.
136. Reeves, S. L., K. J. Dombkowski, H. J. Fullerton, L. M. Cohn and L. D. Lisabeth (2013). "Missed opportunities for transcranial doppler screening among children with sickle cell disease." *Stroke* 44(2).
137. Richard, M., M. A. Mubiri and A. Bioy (2014). "Psychological and developmental points on the patient with sickle cell disease." *Doleurs* 15(6): 278-287.
138. Robitaille, N., E. E. Delvin and H. A. Hume (2006). "Newborn screening for sickle cell disease: A 1988-2003 Quebec experience." *Paediatrics and Child Health* 11(4): 223-227.
139. Rodriguez-Moldes, B., A. J. Carbajo, B. Sanchez, M. Fernandez, M. Gari, M. C. Fernandez, J. Alvarez, A. Garcia and E. Cela (2015). "Primary care follow-up of newborns with sickle cell disease detected in neonatal screening in the Community of Madrid." *Anales de Pediatría* 82(4): 222-227.
140. Rose, N. C. and S. M. Dolan (2012). "Newborn screening and the obstetrician." *Obstetrics and Gynecology* 120(4): 908-917.
141. Roseff, S. D. (2009). "Sickle cell disease: A review." *Immunohematology* 25(2): 67-74.

142. Ross, L. F. (2012). "A re-examination of the use of ethnicity in prenatal carrier testing." *American Journal of Medical Genetics, Part A* 158 A(1): 19-23.
143. Rotz, S., G. Arty, R. Dall'Amico, L. De Zen, F. Zanolli and P. Bodas (2013). "Prevalence of sickle cell disease, hemoglobin S, and hemoglobin C among Haitian newborns." *American Journal of Hematology* 88(9): 827-828.
144. Rwezaula, S., S. Cox, B. Lowe, P. Magesa, A. Massawe, C. Newton, J. Makani, C. Reid, B. Davis, T. Marlow, J. Glanville, A. K. Qureshi and D. Roberts (2011). "Neonatal screening for haemoglobinopathies at Muhimbili National Hospital, Dar es Salaam. A pilot study." *British Journal of Haematology* 153: 27.
145. Saraf, P., S. H. Jacoby, S. Shah, H. Nazir, M. Gimovsky and A. J. Cohen (2013). "Adverse pregnancy outcomes in high risk sickle cell women." *Blood* 122(21).
146. Saul, J. P., P. J. Schwartz, M. J. Ackerman and J. K. Triedman (2014). "Rationale and objectives for ECG screening in infancy." *Heart Rhythm* 11(12): 2316-2321.
147. Scanga, H. L., B. Kladny, G. Updike and L. Krishnamurti (2012). "Integrating screening for sickle cell, cystic fibrosis, and other disorders included in the newborn screen into the workflow of the prenatal clinic." *American Journal of Hematology* 87(7): E28.
148. Schultz, C. L., T. Tchume-Johnson, T. Jackson, H. Enniful-Eghan, M. Schapira and K. Smith-Whitley (2014). "Reproductive decisions in families affected by sickle cell disease." *Blood* 124(21).
149. Schultz, R. K. R., K. S. Baker, J. J. Boelens, C. M. Bollard, R. M. Egeler, M. Cowan, R. Ladenstein, A. Lankester, F. Locatelli, A. Lawitschka, J. E. Levine, M. Loh, E. Nemecek, C. Niemeyer, V. K. Prasad, V. Rocha, S. Shenoy, B. Strahm, P. Veys, D. Wall, P. Bader, S. A. Grupp, M. A. Pulsipher and C. Peters (2013). "Challenges and opportunities for international cooperative studies in pediatric hematopoietic cell transplantation: Priorities of the westhafen intercontinental group." *Biology of Blood and Marrow Transplantation* 19(9): 1279-1287.
150. Scliver, C. R. (2006). "Community genetics and dignity in diversity in the Quebec Network of Genetic Medicine." *Community Genetics* 9(3): 142-152.
151. Serjeant, G. R. (2010). "One hundred years of sickle cell disease." *British Journal of Haematology* 151(5): 425-429.
152. Shook, L., L. E. Crosby and G. F. Atweh (2013). "Health literacy and sickle cell disease: An assessment of adolescents, young adults and caregivers." *Blood* 122(21).
153. Silva, C. D. A., L. B. Baldim, G. C. Nhoncanse, I. D. F. Estevão and D. G. Melo (2015). "Neonatal screening for hemoglobinopathies in São Carlos, São Paulo, Brazil: Analysis of a series of cases." *Revista Paulista de Pediatria* 33(1): 19-27.
154. Silva, C. M., P. Giovani and M. B. Viana (2011). "High reticulocyte count is an independent risk factor for cerebrovascular disease in children with sickle cell anemia." *Pediatric Blood and Cancer* 56(1): 116-121.
155. Sobota, A., V. Sabharwal, G. Fonebi and M. Steinberg (2015). "How we prevent and manage infection in sickle cell disease." *British Journal of Haematology* 170(6): 757-767.
156. Stark, A. P., C. W. Lang and L. F. Ross (2011). "A pilot study to evaluate knowledge and attitudes of Illinois pediatricians toward newborn screening for sickle cell disease and cystic fibrosis." *American Journal of Perinatology* 28(3): 169-176.

157. Strouse, J. J. (2015). "Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?" *Pediatric Blood and Cancer* 62(6): 929-930.
158. Sutton, D., R. Gregg, G. Lowe, S. Pancham, N. Phillips and C. Wright (2011). "Primary care vaccination and antibiotic prophylaxis in patients with sickle cell disease: Auditing NCEPOD recommendations." *British Journal of Haematology* 153: 41-42.
159. Telfer, P. T. (2011). "Management of sickle cell disease: Out-patient and community aspects." *Paediatrics and Child Health* 21(8): 357-362.
160. Telfer, P. T. (2015). "Management of sickle cell disease: Out-patient and community aspects." *Paediatrics and Child Health (United Kingdom)* 25(8): 375-380.
161. Therrell, B. L. and J. Adams (2007). "Newborn screening in North America." *Journal of Inherited Metabolic Disease* 30(4): 447-465.
162. Therrell Jr, B. L., C. Buechner, M. A. Lloyd-Puryear, P. C. van Dyck and M. Y. Mann (2008). "What's new in newborn screening?" *Pediatric Health* 2(4): 411-429.
163. Tijmstra, T., H. Tjeerdema, J. M. Pennings and G. P. A. Smit (2008). "Parents hardly object to neonatal screening." *Tijdschrift voor Kindergeneeskunde* 76(1): 23-26.
164. Traeger-Synodinos, J. and C. L. Harteveld (2014). "Advances in technologies for screening and diagnosis of hemoglobinopathies." *Biomarkers in Medicine* 8(1): 119-131.
165. Tshilolo, L., E. Kafando, M. Sawadogo, F. Cotton, F. Vertongen, A. Ferster and B. Gulbis (2008). "Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: Lessons from pilot studies." *Public Health* 122(9): 933-941.
166. Tuño, K. R., E. E. Ezeanolue, A. Hunt, S. Shahani and W. Whitten-Shurney (2013). "State health departments handling of sickle cell trait results identified through the newborn screening programs." *Journal of Investigative Medicine* 61(1): 165.
167. Upadhye, D., D. Jain, S. Nair, A. Nadkarni, K. Ghosh and R. Colah (2011). "Three non deletional alpha gene variants identified in neonates during newborn screening for sickle cell disorders." *Indian Journal of Hematology and Blood Transfusion* 27(4): 242.
168. Van Der Plas, E. M., X. W. Van Den Tweel, R. B. Geskus, H. Heijboer, B. J. Biemond, M. Peters and K. Fijnvandraat (2011). "Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening." *British Journal of Haematology* 155(1): 106-110.
169. Vansenne, F., C. A. J. M. De Borgie, M. Legdeur, M. O. Spauwen and M. Peters (2011). "Providing genetic risk information to parents of newborns with sickle cell trait: Role of the general practitioner in neonatal screening." *Genetic Testing and Molecular Biomarkers* 15(10): 671-675.
170. Veiga, E., A. Veiga and A. Ramos (2014). "Features of clinical and epidemiological children with sickle cell admitted in teaching hospital alcides carneiro (HEAC), Petrópolis, RJ, Brazil." *Archives of Disease in Childhood* 99: A303.
171. Vetter, V. L. (2014). "Electrocardiographic screening of all infants, children, and teenagers should be performed." *Circulation* 130(8): 688-697.
172. Viana, M. B., P. V. Rezende, M. Murao, J. N. Januário, A. C. L. Chaves and A. C. F. Ribeiro (2009). "Acute splenic sequestration in a cohort of children derived from the Newborn Screening Program for sickle cell anemia in Minas Gerais, Brazil." *American Journal of*

Hematology 84(8): E102.

173. Villanueva, M. A., L. Z. Mays, R. Kalpatthi and G. Woods (2011). "Sickle-hereditary persistence of fetal hemoglobin - An enigma?" *American Journal of Hematology* 86(10): E60.
174. Wang, Y., G. Liu, M. Caggana, J. Kennedy, R. Zimmerman, S. O. Oyeku, E. M. Werner, A. M. Grant, N. S. Green and S. D. Grosse (2015). "Mortality of New York children with sickle cell disease identified through newborn screening." *Genetics in Medicine* 17(6): 452-459.
175. Ware, R. E. (2013). "Hydroxycarbamide: Clinical aspects." *Comptes Rendus - Biologies* 336(3): 177-182.
176. Wilcken, B. and V. Wiley (2008). "Newborn screening." *Pathology* 40(2): 104-115.
177. Wonkam, A. and S. Hurst (2014). "A call for policy action in sub-saharan Africa to rethink diagnostics for pregnancy affected by sickle cell disease: Differential views of medical doctors, parents and adult patients predict value conflicts in cameroon." *OMICS A Journal of Integrative Biology* 18(7): 472-480.
178. Wright, M. M., M. E. Newsome, D. McAllister and L. Wynn (2011). "Project I.N.F.A.N.T CareCard program: A tool to improve access to quality care for children and adults living with sickle cell disease." *American Journal of Hematology* 86(10): E24-E25.
179. Wynn, L., S. Miller, L. Faughnan, Z. Luo, E. Debenham, L. Adix, B. Fish, T. Hustace, T. Kelly, M. Macdermott, J. Marasciulo, B. Martin, J. McDuffie, M. Murphy, B. Rackoff, C. Reed, P. Seaman, G. Thomas and W. Wang (2010) "Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG Study." *Contemporary Clinical Trials* 31, 558-563.